Regulation - Revlimid

Filter

Current filters:

Revlimid

Popular Filters

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

20-08-2014

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued final draft…

BiotechnologyCelgene Corp.Myelodysplastic syndromesOncologyPricingRegulationRevlimidUK

NICE consulting again on Celgene's Revlimid for multiple myeloma

NICE consulting again on Celgene's Revlimid for multiple myeloma

31-07-2014

The UK clinical guidance body, the National Institute for Health and Care Excellence (NICE), is again…

Celgene Corp.ImmunosuppressantslenalidomideOncologyPharmaceuticalRegulationRevlimidUK

NICE draft guidance negative on Celgene’s Revlimid

20-05-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgeneOncologyPricingRegulationRevlimidUK

NICE says better information needed on Celgene’s MM drug

NICE says better information needed on Celgene’s MM drug

14-03-2014

The UK drugs watchdog, the National Institute for Health and care Excellence (NICE) says that, based…

BiotechnologyCelgeneNorthern EuropeOncologyPricingRegulationRevlimidUK

Negative draft NICE guidance on Celgene’s Revlimid for myelodysplastic syndromes

24-10-2013

The UK drug watchdog the National Institute for Health and Care Excellence (NICE) today issued final…

BiotechnologyCelgeneEuropeOncologyRegulationRevlimid

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM

11-07-2013

US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

US FDA backs new indication for Celgene's Revlimid

06-06-2013

The US Food and Drug Administration has approved US biotech firm Celgene's (Nasdaq: CELG) supplemental…

BiotechnologyCelgeneNorth AmericaOncologyRegulationRevlimid

Celgene's Revlimid approved in China for MM; gets PDUFA date in USA for mantle cell lymphoma

12-02-2013

Celgene Corp's (Nasdaq: CELG) European subsidiary revealed that Revlimid (lenalidomide) has been granted…

Asia-PacificBiotechnologyCelgeneNorth AmericaOncologyRegulationRevlimid

Celgene slumps as it pulls new EU indication filing for Revlimid

22-06-2012

Celgene International, the European subsidiary of USA-based Celgene Corp (Nasdaq: CELG), has provided…

BiotechnologyCelgeneEuropeFinancialOncologyPharmaceuticalpomalidomideRegulationRevlimid

US FDA warns on safety of Celgene's Revlimid; new Ph III trial results

11-05-2012

The US Food and Drug Administration this week issued a notification of an increased risk of second primary…

BiotechnologyCelgeneOncologyRegulationResearchRevlimid

Parexel

Parexel

Back to top